CHNQD-03005 

CHNQD-03005 is an orally active anti-inflammatory agent. CHNQD-03005 inhibits the expression of iNOS and COX-2, reduces inflammatory signal transduction, suppresses NO production, and downregulates the pro-inflammatory cytokines TNF-α, IL-6 and IL-1β. CHNQD-03005 can be used in the research of inflammatory diseases such as colitis^[1].

CHNQD-03005 (Compound C13) (24 h) inhibits the production of TNF-α, IL-1β, IL-6 and NO in LPS (HY-D1056)-stimulated RAW264.7 cells, with IC₅₀ values of 0.45 μM, 0.086 μM, 0.095 μM, and 0.038 μM, respectively^[1].
CHNQD-03005 (0.2-6 μM) inhibits the protein expression of iNOS, COX-2 and IL-1β in LPS (HY-D1056)-stimulated RAW264.7 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CHNQD-03005 (1 mg/kg; p.o.; 7-9 days) effectively ameliorates symptoms of DSS (HY-116282C)-induced ulcerative colitis in mice^[1].
CHNQD-03005 (100 mg/kg; p.o.; single administration) exhibits favorable safety, with an oral MTD exceeding 100 mg/kg in male C57BL/6J mice^[1].
CHNQD-03005 (20 mg/kg; p.o.; 21 days) is well tolerated in ICR mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

512.55

C₃₁H₂₈O₇

C=CCOC1=CC=C(C=C1)C2=CC(OC)=C(C(OCC=C)=C2OC)C3=CC=C(C=C3)OC(C4=CC=CO4)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wang CF, et al. Design, semisynthesis, and anti-inflammatory activity evaluation of a terphenyllin compound library for alleviating ulcerative colitis. Eur J Med Chem. 2026;305:118539.  [Content Brief]